As communicated on 26 August 2025, Aptahem has initiated a process to become listed on a U.S. stock exchange, with the goal of achieving a market valuation that better reflects the Company's scientific and clinical progress, securing optimal access to financing for the planned Phase 2 study, and ultimately creating the best possible conditions for successful commercialization of its drug candidate portfolio.

The recently raised capital is assessed by the Company to be sufficient to move forward in this process. However, given the outcome of the rights issue, Aptahem will continue to operate with a slimmed-down organization, retaining only essential in-house staff and ensuring efficient allocation of resources within prioritized areas. The proceeds will primarily be used to cover activities related to the U.S. listing as well as operating costs.

This follows several recently completed important applications to U.S. authorities, which were announced in August 2025:

• to the U.S. Patent and Trademark Office (20 August);
• to the FDA's PreCheck Program(13 August); and
• to the FDA's CNPV Pilot Program (27 August).

Regarding preparations for the planned U.S. listing, the near-term priorities include completing the transition to IFRS accounting standards, preparing for U.S. auditor engagement, and continuing to address the broad range of legal and regulatory requirements needed to take the next steps with the U.S. investors the Company is in dialogue with. Further updates will be provided as the listing process advances.

In parallel, Aptahem will continue its non-capital-intensive efforts to strengthen and maintain relationships with potential partners in the pharmaceutical industry. The goal is to position the Company as strongly as possible for the shortest path to commercial success, in step with steady capitalization and ongoing regulatory and clinical progress.

CEO Mikael Lindstam comments

"I am very grateful for the support we have received from our shareholders. Although the issue was not fully subscribed, the outcome still enables us to hold firm to our strategic direction. We prioritize and remain fully dedicated to the U.S. listing plan and will execute it in a lean and disciplined way. We now begin with the immediate tasks, such as the transition to IFRS, and I look forward to gradually demonstrating our progress to the market as we move forward."

For further information:

Aptahem AB
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
E-mail: ml@aptahem.com

About Aptahem

Aptahem AB (APTA) is a clinical stage biotechnology company that develops RNA-based pharmaceuticals for the treatment of acute, life-threatening conditions in which a combination of coagulation, inflammation and tissue damage are involved. The company's lead candidate, Apta-1, is currently in early clinical phase. Apta-1 has in preclinical studies, by its anti-thrombotic, immunomodulating and tissue repairing characteristics, shown very positive and promising results as treatment for sepsis and critical conditions associated with sepsis. For more information, please visit www.aptahem.com.